A 2026 planning issue for authorisation holders: review the product-information transition before the January 2027 deadline.
Published 8 November 2026
The transition to review
The Commission identifies 29 January 2027 as the end of the packaging and labelling transition for veterinary medicines authorised or registered under the previous framework. EMA’s QRD guidance addresses the associated product-information templates and implementation route. The applicable steps depend on the product’s regulatory history.
Build a product-by-product schedule
Create an inventory of affected authorisations, approved texts, languages, artwork and stock. Check which variations and implementation steps are needed, who owns each task and whether manufacturing and distribution partners can meet the timetable.
Practical contract questions
Review responsibility for artwork changes, obsolete packaging, supply interruptions and regulatory submissions. In a licensing or acquisition transaction, the agreement should allocate the work and costs rather than leaving the issue to general compliance warranties.
The risk of a single portfolio assumption
Two medicines sold by the same business may be at different stages of alignment. A portfolio-wide statement that all labels can remain unchanged until a single date can obscure product-specific obligations. Obtain a regulatory assessment before deciding how remaining stock will be handled.
More insights and archive articles · Explore our services
Discuss your matter
Send a short description, the parties involved and any deadline. We check conflicts and agree the scope and fees before starting work. For urgent matters, telephone our office as well.